• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider

    1/23/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PACB alert in real time by email

    MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Security (GIFS) at the University of Saskatchewan (USask) as the first Revio PacBio Certified Service Provider (CSP) in Canada.

    Known for its leadership in animal, microbial and plant genomics, GIFS offers PacBio's HiFi sequencing technology through its Omics and Precision Analytics Laboratory (OPAL) platform. This provides researchers across Canada and around the world with access to highly accurate long-read sequencing data to support complex genetic studies and practical applications, from agricultural innovation to disease discovery.

    The PacBio Certified Service Provider program ensures that customers worldwide have access to the highest quality sequencing services powered by PacBio technology. By achieving CSP status, GIFS has demonstrated the capability, expertise, and infrastructure required to deliver high-quality PacBio sequencing solutions, including complex genome assemblies, transcriptomics, epigenetics, and other precision applications.

    "Canada is home to a dynamic genomics research community that plays a key role in addressing global challenges such as food security, agricultural sustainability, and precision health," said James Hudson, Senior Director of Americas Sales at PacBio. "We are proud to welcome GIFS as Canada's first Revio PacBio Certified Service Provider. This certification provides Canadian researchers access to PacBio's highly accurate HiFi sequencing technology through a trusted partner, enabling them to generate critical insights with exceptional precision and quality."

    GIFS' OPAL platform provides full-service genomics solutions that include automation, bioinformatics, and advanced data analysis, positioning them as a valuable resource for researchers looking to tackle large-scale genomic projects. Through PacBio's HiFi sequencing technology, GIFS will empower scientists to address emerging challenges.

    "The Global Institute for Food Security's world-class technology platforms help researchers and organizations to scale and accelerate their research and development. As a PacBio Certified Service Provider, our partners know they can depend on GIFS to deliver high-quality, HiFi data to advance their projects," said Dr. Steven Webb (PhD), GIFS CEO. "Today, GIFS' Omics and Precision Analytics Laboratory uses high-throughput automated workflows to help our partners get the most from PacBio's long-read sequencing technologies. The sequencing results we deliver are supported by GIFS' automated bioinformatics and visualizations pipelines, ensuring our partners receive both high-quality data and critical analysis that can help them to discover, develop, and deliver." 

    For more on the comprehensive services that GIFS provides, see gifs.ca/partners.

    The addition of GIFS to PacBio's growing Certified Service Provider network highlights PacBio's commitment to making its advanced sequencing solutions accessible to researchers worldwide.

    About PacBio

    PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

    PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

    About the Global Institute for Food Security at the University of Saskatchewan

    The Global Institute for Food Security (GIFS) at the University of Saskatchewan (USask) works with partners to discover, develop, and deliver innovative solutions for the production of globally sustainable food. Serving as ‘agriculture's innovation catalyst,' GIFS is connecting the agri-food ecosystem, advancing innovation, and bridging the gap to commercialization to deliver resilient and sustainable food security for all stakeholders. For more information, visit gifs.ca.

    Forward Looking Statements

    This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, and benefits or expected benefits of using, PacBio products or technologies, including the ability of GIFS to deliver high-quality sequencing solutions; enabling researchers to generate critical insights and address emerging challenges using PacBio technology through GIFS; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, the difficulty of generating discoveries in complicated areas of biology; potential performance, quality and regulatory issues; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

    Contacts:

    PacBio

    For investors:

    Todd Friedman, [email protected]

    For media:

    [email protected]

    Global Institute for Food Security:

    Communications:

    Dan Yates, [email protected]



    Primary Logo

    Get the next $PACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PACB

    DatePrice TargetRatingAnalyst
    3/6/2026$1.50Equal Weight → Underweight
    Barclays
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    More analyst ratings

    $PACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research

    MENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced a collaboration with DNAstack to power the world's first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the collaboration enables secure international research — allowing genomic insights to travel across borders while sensitive data remains under institutional control. Participating institutions connect HiFi whole genome sequencing data and associated metadata within a highly secure federated environment. Hosted by DNAstack and accessible at https://hifisolves.org, the platfor

    2/24/26 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio to Participate in the TD Cowen 46th Annual Health Care Conference

    MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026, at 2:30 PM ET in Boston, MA. A live webcast of the event can be accessed at the company's investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event. About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and cli

    2/18/26 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gibson Christopher was granted 53,913 shares (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/5/26 8:43:24 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Gibson Christopher

    3 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/5/26 8:39:25 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Henry Christian O sold $18,920 worth of shares (12,497 units at $1.51), decreasing direct ownership by 0.35% to 3,581,813 units (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/4/26 5:55:22 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pacific Biosciences downgraded by Barclays with a new price target

    Barclays downgraded Pacific Biosciences from Equal Weight to Underweight and set a new price target of $1.50

    3/6/26 8:26:02 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences downgraded by UBS

    UBS downgraded Pacific Biosciences from Buy to Neutral

    11/11/24 9:44:33 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Pacific Biosciences with a new price target

    Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00

    6/3/24 8:16:36 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    SEC Filings

    View All

    Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    3/6/26 4:06:02 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    3/5/26 8:34:48 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by Pacific Biosciences of California Inc.

    144 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    3/3/26 4:20:56 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/6/24 5:36:07 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

    SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:48:11 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Leadership Updates

    Live Leadership Updates

    View All

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

    MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

    5/22/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jim Gibson to join PacBio as Chief Financial Officer

    MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

    3/27/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Financials

    Live finance-specific insights

    View All

    PacBio Announces Fourth Quarter and Full Year 2025 Financial Results

    MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results:  Q4 2025Q4 2024FY 2025FY 2024Revenue (in millions)$44.6$39.2$160.0$154.0Consumable revenue (in millions)$21.6$18.8$82.0$70.3Instrument revenue (in millions)$17.3$15.3$53.8$65.8Service and other revenue (in millions)$5.7$5.1$24.2$17.9RevioTM system placements21236197VegaTM system placements4271407Annualized Revio pull-through per system~$242,000~$240,000~$233,000~$252,000Ending cash, cash equivalents, and investments(in millions)$279.5$389.9   Gross margin, operating expenses, net inco

    2/12/26 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, February 12, 2026, at 5:00 pm ET (2:00 pm PT) Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advan

    1/27/26 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

    MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively. "We finished the year with strong momentum driven by increased Revio and Vega sales as well as record consumables revenue, reflecting meaningful traction across a range of clinical sequencing applications," said Christian Henry, President and CEO of PacBio. "In 2025, we also significantly reduced our cash burn and strengthened our financial profile. Look

    1/12/26 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials